LT - It sure doesn't make sense that Lippa et al. has put so much effort (i.e., publishing) on ampakines where their patents have expired (e.g., CX717). It appears the entire ampakine platform has been repatented based on application (oral vs. injection), specific target (e.g., brain location) and perhaps new dosages. I had thought that information from the US patent office as to new patent applications, pending etc. would be readily available by an inquiry via AI. It is not. Very murky, indeed. But from what I have gleaned, the entire RSPI ampakine platform has been repatented several years ago.
Market Data 
Markets 
AI
